.12 Mar 2020 08:56
Highly conservative scenario:
20m tests per year = £100m sales, 50% GPM, £50m x P/E of around 10 = £500m mcap
Upper target (assuming they ramp up production capacity, which I expect)
30m tests = £150m sales 50% GPM, £75m profit x P/E of 10 = £750m mcap
Bare in mind GPM is likely to be closer to 60% and P/E's are typically 15-20+ for pharma's
Note: excludes other aspects of business which will benefit from the exposure, and various FDA approvals/NHS orders etc which will undoubtedly magnify sales significantly